Eisai Co., Ltd. (ESAIY) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は Tokyo, 日本. 現CEOは Haruo Naito.
ESAIY を有する IPO日 2023-02-02, 11,067 名の正社員, に上場 Other OTC, 時価総額 $9.03B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that engages in the research, development, manufacture, and commercialization of prescription medications across multiple therapeutic areas. The company's product portfolio includes Dayvigo for insomnia, Lenvima for various cancers including thyroid and renal cell carcinoma, Aricept for Alzheimer's disease, Halaven for breast cancer, and Fycompa for epilepsy, among other medications addressing neurology, oncology, gastroenterology, and other specialties. Eisai maintains a strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin, an antibody drug conjugate. The company operates globally with a strong presence in Japan and serves both domestic and international markets through its research and manufacturing operations.
